Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. Novartis overview Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 28, 2023
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. It was also under development for the treatment of idiopathic/primary membranous nephropathy.
Pharmaceutical Technology
FEBRUARY 28, 2023
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. It was also under development for the treatment of idiopathic/primary membranous nephropathy.
The Pharma Data
MAY 8, 2021
Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. About Sandoz.
Pharmaceutical Technology
FEBRUARY 18, 2023
The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Gevokizumab Overview Gevokizumab (XOMA-052) is developing gevokizumab for the treatment of metastatic colorectal cancer gastroesophageal cancer and colon cancer.
The Pharma Data
MAY 2, 2021
Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. About Sandoz.
Expert insights. Personalized for you.
172 
Let's personalize your content